Abstract
Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Current Pharmaceutical Biotechnology
Title:Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Volume: 15 Issue: 7
Author(s): Francisca Araujo, Neha Shrestha, Pedro L. Granja, Jouni Hirvonen, Hélder A. Santos and Bruno Sarmento
Affiliation:
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Abstract: Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Export Options
About this article
Cite this article as:
Araujo Francisca, Shrestha Neha, Granja L. Pedro, Hirvonen Jouni, Santos A. Hélder and Sarmento Bruno, Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects, Current Pharmaceutical Biotechnology 2014; 15 (7) . https://dx.doi.org/10.2174/1389201015666140915150312
DOI https://dx.doi.org/10.2174/1389201015666140915150312 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Molecular Concept of Atheromatous Plaques
Current Drug Targets Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Novel Optical Techniques for Imaging Microcirculation in the Diabetic Foot
Current Pharmaceutical Design Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology Calcifediol – More than the Stepchild of CKD-MBD Therapy?
Current Vascular Pharmacology Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design A Review of Bisindolylmethane as an Important Scaffold for Drug Discovery
Current Medicinal Chemistry Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Molecular Imaging of Diabetic Pancreas
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design <i>Nigella Sativa</i> (Black Seeds), A Potential Herb for the Pharmacotherapeutic Management of Hypertension - A Review
Current Cardiology Reviews Tumor-Induced Metabolism and T Cells Located in Tumor Environment
Current Cancer Drug Targets Tea and Health: Studies in Humans
Current Pharmaceutical Design The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets